Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.
Monitor implementation of The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinationals, and the orphan drug tax credit.
Orphan Drug Act and issues regarding access to care for those with rare diseases. H.R. 5803, SAFETY Act of 2018, S. 2680, Opioid Crisis Response Act of 2018, S. 2891, Fighting the Opioid Epidemic with Sunshine Act of 2018, S. 3000, Patient Advocacy Transparency Act, and H.R. 6, SUPPORT for Patients and Communities Act as they related to issues regarding controlled substances. Monitored issues related to newborn screening.
Monitored H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act and Continuing Appropriations Act. Monitored H.R. 695, Further Additional Continuing Appropriations Act of 2019.
Duration: June 3, 2016
to
December 31, 2018
General Issues: Medicare/Medicaid , Taxation/Internal Revenue Code , Health Issues , Budget/Appropriations
Spending: about $525,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Office of the Vice President of the United States
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Mary Beth Savary Taylor Joint Economic Committee, General Counsel; U.S. Senator Connie Mack, Legislative Assistant
Rachel Jones Hensler U.S. Senate Budget Committee, Tax Policy Dir.; Office of U.S. Senator Fred Thompson, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Assistant; Office of U.S. Senator Dave Durenberger, Legislative Correspondent
Emily Porter Ofce of Spkr(Rep.Boehner),Asst to Spkr,Policy;Ofce of Min.Leader(Rep.Boehner),Plcy Adv;Ofce of the Maj. Ldr(Rep. Boehner),Plcy Adv;Cmte Ed & the Wrkfrc(Rep.Boehner),Coaltions Dir. for Educ Plcy; Rep.Trent Franks,Sr.Leg.Asst; Rep.Tom Tancredo,Leg.Asst
Katherine Raab House Cmte on Energy and Commerce, Prof. Staff; Congressman Mary Bono, Leg. Asst.; Congressman Elton Gallegly, Leg. Asst.; Congressman Michael Bilirakis, Leg. Asst.; Congressman Michael Bilirakis, Leg. Corr.; Congressman Michael Bilirakis, Staff Asst
Jeff Choudhry U.S. Rep. Trent Franks, Legislative Director; U.S. Rep. Trent Franks, Legislative Assistant / Staff Assistant; House Small Business Committee, Intern
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
THE NICKLES GROUP, LLC terminated an engagement in which they represented Shire Pharmaceuticals LLC on Jan. 18, 2019.
Original Filing: 301008137.xml
Lobbying Issues
Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinationals, and the orphan drug tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Orphan Drug Act and issues regarding access to care for those with rare diseases. H.R. 5803, SAFETY Act of 2018, S. 2680, Opioid Crisis Response Act of 2018, S. 2891, Fighting the Opioid Epidemic with Sunshine Act of 2018, S. 3000, Patient Advocacy Transparency Act, and H.R. 6, SUPPORT for Patients and Communities Act as they related to issues regarding controlled substances. Monitored issues related to newborn screening.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H.R. 6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act and Continuing Appropriations Act. Monitored H.R. 695, Further Additional Continuing Appropriations Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on Oct. 22, 2018.
Original Filing: 300997728.xml
Lobbying Issues
Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids). S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinationals, and the orphan drug tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Orphan Drug Act and issues regarding access to care for those with rare diseases. H.R. 5803, SAFETY Act of 2018, S. 2680, Opioid Crisis Response Act of 2018, S. 2891, Fighting the Opioid Epidemic with Sunshine Act of 2018, S. 3000, Patient Advocacy Transparency Act, and H.R. 6, SUPPORT for Patients and Communities Act as they related to issues regarding controlled substances.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on July 20, 2018.
Original Filing: 300973943.xml
Lobbying Issues
Issues related to pharmaceutical prices. Issues regarding the Self-Administered Drug (SAD) list. Issues related to opioids, including H.R. 6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinationals, and the orphan drug tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017 and monitored implementation. Orphan Drug Act and issues regarding access to care for those with rare diseases. Issues regarding opioids, including H.R. 5803, SAFETY Act of 2018, S. 2680, Opioid Crisis Response Act of 2018, S. 2891, Fighting the Opioid Epidemic with Sunshine Act of 2018 and S. 3000, Patient Advocacy Transparency Act, and H.R. 6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on April 19, 2018.
Original Filing: 300949138.xml
Lobbying Issues
H.R. 1892, Bipartisan Budget Act, H.R. 3178, Medicare Part B Improvement Act of 2017, and S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 and issues related to reimbursement for home infusion. Issues related to pharmaceutical prices. Issues regarding the Self-Administered Drug (SAD) list. H.R. 1625, Consolidated Appropriations Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of H.R. 1, The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinationals, and the orphan drug tax credit.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2368, Right to Try Act. H.R. 878, Right to Try Act of 2017. H.R. 5247/ S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Issues regarding access to care for those with rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1625, Consolidated Appropriations Act of 2018. H.R. 1892, Bipartisan Budget Act of 2018 and issues concerning the home infusion benefit.
4th Quarter, 2017
In Q4, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on Jan. 22, 2018.
Original Filing: 300936749.xml
Lobbying Issues
H.R. 3178, Medicare Part B Improvement Act of 2017 and S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 and issues related to reimbursement for home infusion. Issues related to pharmaceutical prices. Issues regarding the Self-Administered Drug (SAD) list.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1, The Tax Cut and Jobs Act, as it relates to corporate tax reform, the taxation of multinationals, and the orphan drug tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Issues regarding access to care for those with rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H. Con. Res. 71, The FY 2018 Budget Resolution, as it relates to tax reconciliation instructions. H.J. Res 123, Making further continuing appropriations for FY 2018 and H.R.1370, An Act to amend the Homeland Security Act of 2002, as it relates to further additional appropriations for 2018 and issues concerning the home infusion benefit.
3rd Quarter, 2017
In Q3, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on Oct. 19, 2017.
Original Filing: 300909843.xml
Lobbying Issues
H.R. 3178, Medicare Part B Improvement Act of 2017 and S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 and issues related to home infusion and reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices. H.R. 1628, The American Health Care Act of 2017 including the Better Health Reconciliation Act and the Graham Cassidy amendment and issues regarding access to care for those with rare diseases. H.R. 3823, The Disaster Tax Relief and Airport and Airway Extension Act of 2017, as it relates to extension of the IVIG Demo. Issues regarding the Self-Administered Drugs (SAD) list.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored H.R. 1628, the American Health Care Act of 2017, as it relates to the branded drug fee.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 934, H.R. 2430, and Public Law 115-52, The FDA Reauthorization Act of 2017 and issues regarding right to try and clinical superiority. S. 204, Trickett Wendler Right to Try Act of 2017. H.R. 878, Right to Try Act of 2017. S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 and issues regarding care for chronic care disease patients. H.R. 1628, The American Health Care Act of 2017 including the Better Health Reconciliation Act and the Graham Cassidy amendment and issues regarding access to care for those with rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H. Con. Res. 71, The FY 2018 Budget Resolution, as it relates to tax reconciliation instructions.
3rd Quarter, 2017
THE NICKLES GROUP, LLC amended a lobbying report for representation of Shire Pharmaceuticals LLC in Q32017 on Oct. 19, 2017.
Original Filing: 300909921.xml
Lobbying Issues
H.R. 3178, Medicare Part B Improvement Act of 2017 and S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 and issues related to home infusion and reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices. H.R. 1628, The American Health Care Act of 2017 including the Better Health Reconciliation Act and the Graham Cassidy amendment and issues regarding access to care for those with rare diseases. H.R. 3823, The Disaster Tax Relief and Airport and Airway Extension Act of 2017, as it relates to extension of the IVIG Demo. Issues regarding the Self-Administered Drugs (SAD) list.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored H.R. 1628, the American Health Care Act of 2017, as it relates to the branded drug fee.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 934 / H.R. 2430, The FDA Reauthorization Act of 2017 and issues regarding right to try and clinical superiority. S. 204, Trickett Wendler Right to Try Act of 2017. H.R. 878, Right to Try Act of 2017. S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 and issues regarding care for chronic care disease patients. H.R. 1628, The American Health Care Act of 2017 including the Better Health Reconciliation Act and the Graham Cassidy amendment and issues regarding access to care for those with rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H. Con. Res. 71, The FY 2018 Budget Resolution, as it relates to tax reconciliation instructions.
3rd Quarter, 2017
THE NICKLES GROUP, LLC amended a lobbying report for representation of Shire Pharmaceuticals LLC in Q32017 on Oct. 19, 2017.
Original Filing: 300910717.xml
Lobbying Issues
H.R. 3178, Medicare Part B Improvement Act of 2017 and S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 and issues related to home infusion and reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices. H.R. 1628, The American Health Care Act of 2017 including the Better Care Reconciliation Act and the Graham Cassidy amendment and issues regarding access to care for those with rare diseases. H.R. 3823, The Disaster Tax Relief and Airport and Airway Extension Act of 2017, as it relates to extension of the IVIG Demo. Issues regarding the Self-Administered Drugs (SAD) list.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored H.R. 1628, the American Health Care Act of 2017, as it relates to the branded drug fee.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 934 / H.R. 2430, The FDA Reauthorization Act of 2017 and issues regarding right to try and clinical superiority. S. 204, Trickett Wendler Right to Try Act of 2017. H.R. 878, Right to Try Act of 2017. S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 and issues regarding care for chronic care disease patients. H.R. 1628, The American Health Care Act of 2017 including the Better Care Reconciliation Act and the Graham Cassidy amendment and issues regarding access to care for those with rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H. Con. Res. 71, The FY 2018 Budget Resolution, as it relates to tax reconciliation instructions.
2nd Quarter, 2017
In Q2, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on July 20, 2017.
Original Filing: 300896935.xml
Lobbying Issues
Issues related to home infusion and reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices. H.R. 1628, The American Health Care Act of 2017 and issues regarding access to care for those with rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored H.R. 1628, the American Health Care Act of 2017, as it relates to the branded drug fee.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 934 and H.R. 2430, The FDA Reauthorization Act of 2017 and issues regarding right to try and clinical superiority. S. 204, Trickett Wendler Right to Try Act of 2017. S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 and issues regarding care for chronic care disease patients.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on April 20, 2017.
Original Filing: 300874733.xml
Lobbying Issues
Issues related to home infusion and reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored H.R. 1628, the American Health Care Act of 2017, as it relates to the branded drug fee.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues concerning extension of the rare pediatric disease priority review voucher program. Issues regarding care for chronic care disease patents. Issues regarding the User Fee Agreements. Monitored H.R. 1628, the American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on Jan. 18, 2017.
Original Filing: 300849494.xml
Lobbying Issues
H.R. 34, The 21st Century Cures Act; S. 275 / H.R. 605, The Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration; H.R. 2028, Further Continuing and Security Assistance Appropriations Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored issues related to the Treasury Department's proposed Sect. 385 regulation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 34, The 21st Century Cures Act and issues concerning extension of the rare pediatric disease priority review voucher program. Issues regarding care for chronic care disease patients.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC , earning $52,500. The report was filed on Oct. 20, 2016.
Original Filing: 300838243.xml
Lobbying Issues
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, The Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored issues related to the Treasury Department's proposed Sect. 385 regulation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, The 21st Century Cures Act and the Innovations Initiative. S. 1878, Advancing Hope Act of 2016, concerning extension of the pediatric priority review voucher program. Issues concerning care for chronic care disease patients.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, THE NICKLES GROUP, LLC lobbied for Shire Pharmaceuticals LLC . The report was filed on July 20, 2016.
Original Filing: 300817699.xml
Lobbying Issues
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform and the taxation of multinational corporations. Issues related to the orphan drug tax credit. Monitored issues related to the Treasury Department's proposed Sect. 385 regulation. Monitored issues related to S. 2328, PROMESA.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, The 21st Century Cures Act and the Innovations Initiative. S. 1878, Advancing Hope Act of 2016, concerning extension of the pediatric priority review voucher program. Issues concerning care for chronic care disease patients.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
The Nickles Group, LLC filed a lobbying registration on July 13, 2016 to represent Shire Pharmaceuticals LLC, effective June 3, 2016.
Original Filing: 300809228.xml
Issue(s) they said they’d lobby about: Biologics drugs, tax and trade issues. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...